Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05363111 · ClinicalTrials.gov registry record · Phase 1

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

A Phase 1 study of Refractory Plasma Cell Myeloma and Recurrent Plasma Cell Myeloma, sponsored by City of Hope Medical Center.

Recruiting
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT05363111 is a Phase 1 study of Refractory Plasma Cell Myeloma and Recurrent Plasma Cell Myeloma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 15 participants, below the 46-participant average among 25 other Refractory Plasma Cell Myeloma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05363111, a Phase 1 study of Refractory Plasma Cell Myeloma and Recurrent Plasma Cell Myeloma, is actively recruiting participants, sponsored by City of Hope Medical Center.

RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-DOTA-daratumumab) in treating patients with multiple myeloma that does not respond to treatment (refractory) or that has come back (recurrent). Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. 111In-DOTA-daratumumab and 225Ac-DOTA-daratumumab are forms of radioimmunotherapy in which a monoclonal antibody, daratumumab, has been linked to a radiotracer to allow for targeted delivery of the treatment to cancer cells. Giving all three together may kill more cancer cells.

Conditions Studied

Refractory Plasma Cell Myeloma Recurrent Plasma Cell Myeloma

Interventions

  • BIOLOGICAL Daratumumab
  • BIOLOGICAL Actinium Ac 225-DOTA-Daratumumab
  • BIOLOGICAL Indium In 111-DOTA-Daratumumab

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-11-22
Est. Completion 2027-03-23
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05363111

The ClinicalTrials.gov registry entry for NCT05363111 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 46-participant average among 25 other Refractory Plasma Cell Myeloma trials with a reported enrollment target (67% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Refractory Plasma Cell Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Daratumumab is the first listed.

NCT05363111 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05363111 about?

NCT05363111 is a clinical study titled "Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma". This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-DOTA-daratumumab) in treating patients with multiple myeloma that does not respond to treatment (ref...

What is the current status of trial NCT05363111?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-11-22. Estimated completion is 2027-03-23.

What conditions does trial NCT05363111 study?

This clinical trial studies the following conditions: Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma.

What interventions are being tested in trial NCT05363111?

The interventions under investigation include: Daratumumab (BIOLOGICAL), Actinium Ac 225-DOTA-Daratumumab (BIOLOGICAL), Indium In 111-DOTA-Daratumumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT05363111?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05363111 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Plasma Cell Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Plasma Cell Myeloma

All registered trials for this condition

Recurrent Plasma Cell Myeloma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.